Immune Pharmaceuticals Inc (fka IMNPQ)

[Investor100]

Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) Insiders Look Optimistic About Prospects

No question this stock is getting some solid PR in the markets.

Strong inside buying as reflective in this article and one that I have highlighted as well...

http://reviewfortune.com/2016/07/12/immune-pharmaceuticals-inc-nasdaqimnp-insiders-look-optimistic-about-prospects/

Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) up 10.84 per cent in the past week, is under coverage of 3 analysts who collectively recommend a buy rating on stock. 3 of the analysts have a buy or better rating; the 0 sells versus 0 underperforms. The 2 equity analysts who rate the stock have an average target price at $2, with individual targets ranging between $1 and $3. The shares closed last trade at $0.46, implying that analysts see shares rising about 334.78 per cent in 12 months’ time.

Insider Activity: Insiders look optimistic about the prospects of the company that they seem to accumulate shares while they are -36.99 down so far this year. A CEO, 10% Owner at Immune Pharmaceuticals, Inc. (IMNP) purchased shares in the company in a transaction completed on Tuesday January 26, 2016. Teper Daniel Gedeon accumulated 42,000 shares in the company at an average price of $0.59 and ended up spending $24,780 in the investment. Teper Daniel Gedeon now have 4,810,905 shares in the company after this transaction. A CEO, 10% Owner in the company, Teper Daniel Gedeon, on Tuesday January 19, 2016 spent $25,190 from the purchase of 44,200 shares at $0.59 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings Roundup: In the last fiscal quarter alone, Immune Pharmaceuticals, Inc. generated around $0 in revenue and net income of -$0.17/share. That compares with the consensus estimate $0 and -$0.15/share, respectively. For the prior quarter revenue for the company hit $0, with earnings at -$0.27/share.

Immune Pharmaceuticals, Inc. (IMNP) Analyst Coverage

ROTH Capital has been a brokerage house following shares of Immune Pharmaceuticals, Inc. (IMNP), so its rating change is noteworthy. The stock was initiated at Buy, wrote analysts at ROTH Capital, in a note issued to clients on Thursday October 08, 2015. There was another key note issued by Chardan Capital Markets on Monday March 09, 2015. The firm launched coverage on IMNP at Buy.

Price Momentum: Despite the 15.14% increase in value, the stock’s new closing price represents a -76.41% fall in value from company’s one year high of $1.95. The stock is currently holding below its 50 day moving average of $23.5 and above its 200 day moving average of $0.39. Over the last three months and over the last six months, the shares of Immune Pharmaceuticals, Inc. (IMNP), have changed -31.19% and 0.46%, respectively.

Investor 100